Mild Asthma

Respiratory
1
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
1 program
1
QMF149 150/80 μgPhase 31 trial
Active Trials
NCT02892344Completed802Est. Nov 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NovartisQMF149 150/80 μg

Clinical Trials (1)

Total enrollment: 802 patients across 1 trials

NCT02892344NovartisQMF149 150/80 μg

Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma

Start: Jan 2017Est. completion: Nov 2018802 patients
Phase 3Completed

Related Jobs in Respiratory

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space